Thrivent Financial for Lutherans
ACAD icon

Thrivent Financial for Lutherans’s Acadia Pharmaceuticals ACAD Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Sell
93,741
-1,099
-1% -$24.2K ﹤0.01% 1422
2026
Q1 		$2.11M Sell
94,840
-4,415
-4% -$106K ﹤0.01% 1402
2025
Q4 		$2.65M Buy
99,255
+9,186
+10% +$220K ﹤0.01% 1284
2025
Q3 		$1.92M Sell
90,069
-998
-1% -$23.6K ﹤0.01% 1377
2025
Q2 		$1.96M Buy
91,067
+626
+0.7% +$11.6K ﹤0.01% 1371
2025
Q1 		$1.5M Buy
+90,441
New +$1.64M ﹤0.01% 1447
2024
Q3 		– Sell
-78,292
Closed -$1.27M – 2507
2024
Q2 		$1.27M Sell
78,292
-3,343
-4% -$54K ﹤0.01% 1705
2024
Q1 		$1.51M Buy
81,635
+23,790
+41% +$589K ﹤0.01% 1622
2023
Q4 		$1.81M Buy
57,845
+46,918
+429% +$1.12M ﹤0.01% 1445
2023
Q3 		$228K Sell
10,927
-195,729
-95% -$5.32M ﹤0.01% 2366
2023
Q2 		$4.95M Sell
206,656
-59,988
-22% -$1.33M 0.01% 857
2023
Q1 		$5.02M Buy
266,644
+184,505
+225% +$3.51M 0.01% 809
2022
Q4 		$1.31M Sell
82,139
-87,367
-52% -$1.37M ﹤0.01% 1558
2022
Q3 		$2.77M Buy
+169,506
New +$2.75M 0.01% 1032
2022
Q1 		– Sell
-348,107
Closed -$8.13M – 2494
2021
Q4 		$8.13M Sell
348,107
-363,060
-51% -$7.3M 0.02% 742
2021
Q3 		$11.8M Sell
711,167
-10,379
-1% -$200K 0.02% 618
2021
Q2 		$17.6M Sell
721,546
-165,367
-19% -$3.73M 0.04% 498
2021
Q1 		$22.9M Buy
886,913
+96,836
+12% +$4.26M 0.05% 407
2020
Q4 		$42.2M Buy
790,077
+14,925
+2% +$741K 0.1% 269
2020
Q3 		$32M Buy
+775,152
New +$33.5M 0.09% 281

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thrivent Financial for Lutherans's ACAD Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Acadia Pharmaceuticals (ACAD) stake by 1.2% in Q2 2026, selling an estimated $24.2K and leaving 93,741 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

Thrivent Financial for Lutherans first reported a position in ACAD in Q3 2020 and has held it in 20 quarters since. The position peaked at $42.2M in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Thrivent Financial for Lutherans held 93,741 shares of Acadia Pharmaceuticals worth $2.37M as of Q2 2026.
  • Thrivent Financial for Lutherans sold 1,099 Acadia Pharmaceuticals shares in Q2 2026, an estimated $24.2K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1422 holding.
  • Thrivent Financial for Lutherans first reported a position in Acadia Pharmaceuticals in Q3 2020 and has held it in 20 quarters since.
  • Thrivent Financial for Lutherans's Acadia Pharmaceuticals position peaked at $42.2M in Q4 2020.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.